Fig. 4: Comparable inhibition of primary tumour growth in vivo with concurrent and sequential combination strategies. | British Journal of Cancer

Fig. 4: Comparable inhibition of primary tumour growth in vivo with concurrent and sequential combination strategies.

From: Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer

Fig. 4

Sequential versus concurrent combination treatment strategies were tested in three orthotopic xenografts with different tumour kinetics (a). Three TNBC models included MX1 (top row), HCC1806 (middle row), and MDAMB231 (bottom row). N = 8–14 mice per treatment group. Primary tumour growth rates are shown in (b, c, d). The x axis indicates days post treatment, where day 0 indicates the day before treatment. The y axis indicates normalised tumour volumes in which ratios of the tumour volumes on day x were divided by the tumour volumes on day 0 for that mouse. Ex vivo primary tumour volumes are quantified in (e, g, i). Data are represented as mean +/– SEM. ANOVA with post test for multiple comparisons was performed. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. Representative images of ex vivo tumours are shown in (f, h, j). i.p. intraperitoneally, o.g. oral gavage.

Back to article page